| 000 | 01724 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517083643.0 | ||
| 264 | 0 | _c20161223 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1536-4844 | ||
| 024 | 7 |
_a10.1097/MIB.0000000000000709 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGils, Ann | |
| 245 | 0 | 0 |
_aHarmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. _h[electronic resource] |
| 260 |
_bInflammatory bowel diseases _cApr 2016 |
||
| 300 |
_a969-75 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 |
_aBiological Assay _xmethods |
| 650 | 0 | 4 |
_aBiosimilar Pharmaceuticals _xtherapeutic use |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xblood |
| 650 | 0 | 4 |
_aCrohn Disease _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Immunologic |
| 650 | 0 | 4 |
_aEnzyme-Linked Immunosorbent Assay _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfliximab _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aVan Stappen, Thomas | |
| 700 | 1 | _aDreesen, Erwin | |
| 700 | 1 | _aStorme, Ruth | |
| 700 | 1 | _aVermeire, Séverine | |
| 700 | 1 | _aDeclerck, Paul J | |
| 773 | 0 |
_tInflammatory bowel diseases _gvol. 22 _gno. 4 _gp. 969-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MIB.0000000000000709 _zAvailable from publisher's website |
| 999 |
_c25806588 _d25806588 |
||